The US FDA approved the TTR-stabilizing drug for ATTR-CM, with the drugmaker pricing it below that of Pfizer’s Vyndaqel/Vyndamax.
BridgeBio’s Attruby (acoramidis) has the potential to be a highly competitive treatment for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) with its recent US Food and Drug Administration approval, thanks to the drug’s favorable labeling and lower price.
The FDA approved Attruby late on 22 November based on results from the Phase III ATTRibute-CM study, in which the...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.
In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
